Cargando…
Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640
Pancreatic cancer remains extremely difficult to treat, with the average lifespan following diagnosis being only 3-6 months, resulting in a death to incidence ratio of 0.94. A major reason for this high mortality rate is resistance to the main chemotherapeutic agent used to treat this disease, gemci...
Autores principales: | Lewis, Clayton S., Voelkel-Johnson, Christina, Smith, Charles D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312377/ https://www.ncbi.nlm.nih.gov/pubmed/27517489 http://dx.doi.org/10.18632/oncotarget.11112 |
Ejemplares similares
-
The sphingosine kinase 2 inhibitor ABC294640 inhibits cervical carcinoma cell growth
por: Xu, Ling, et al.
Publicado: (2017) -
Sphingosine kinase 2 inhibitor ABC294640 displays anti-epithelial ovarian cancer activities in vitro and in vivo
por: Song, Keqi, et al.
Publicado: (2019) -
Targeting Sphingosine Kinase by ABC294640 against Diffuse Intrinsic Pontine Glioma (DIPG)
por: Dai, Lu, et al.
Publicado: (2020) -
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells
por: Ding, Xiwei, et al.
Publicado: (2016) -
Sphingosine kinase 2 inhibitor ABC294640 suppresses neuronal excitability and inhibits multiple endogenously and exogenously expressed voltage-gated ion channels in cultured cells
por: Zhang, Fei, et al.
Publicado: (2020)